SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-22-028587
Filing Date
2022-08-09
Accepted
2022-08-09 07:25:51
Documents
83
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 SYRS-Q2-2022 syrs-10q_20220630.htm   iXBRL 10-Q 2870975
2 EX-31.1 syrs-ex311_7.htm EX-31.1 17972
3 EX-31.2 syrs-ex312_6.htm EX-31.2 17934
4 EX-32.1 syrs-ex321_9.htm EX-32.1 5982
5 EX-32.2 syrs-ex322_8.htm EX-32.2 5930
  Complete submission text file 0001564590-22-028587.txt   10976428

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA syrs-20220630.xsd EX-101.SCH 78329
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE syrs-20220630_cal.xml EX-101.CAL 61880
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE syrs-20220630_def.xml EX-101.DEF 259120
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE syrs-20220630_lab.xml EX-101.LAB 566425
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syrs-20220630_pre.xml EX-101.PRE 459629
77 EXTRACTED XBRL INSTANCE DOCUMENT syrs-10q_20220630_htm.xml XML 2127774
Mailing Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140
Business Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140 617-744-1340
Syros Pharmaceuticals, Inc. (Filer) CIK: 0001556263 (see all company filings)

IRS No.: 453772460 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37813 | Film No.: 221146397
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences